382. Reduction of Staphylococcus aureus Carriage by Non-Antibiotic NOZINŽ Nasal SanitizerŽ Antiseptic
Session: Poster Abstract Session: MRSA, MSSA, Enterococci
Thursday, October 3, 2013
Room: The Moscone Center: Poster Hall C
Posters
  • poster_final2_1024.pdf (438.0 kB)
  • Background: Healthcare professionals (HCP) that are nasal S. aureus carriers may be a source of transmission of this organism to their patients.  Antibiotics such as mupirocin have been used successfully to control nasal colonization in pre-surgical patients, but this practice is unlikely to be useful for HCP with constant exposure to S. aureus and is likely to lead to antibiotic resistance.  In preliminary clinical testing, NOZIN® Nasal Sanitizer® has been shown to reduce harmful microbes.

    Methods: We conducted a double-blinded treatment effectiveness pilot study of HCP with culture-proven nasal S. aureus colonization within the previous 10 days.  HCP with positive cultures were treated with NOZIN® or placebo at 0 hour, 4 hours, and 8 hours.  Nasal vestibular samples were collected at time 0 prior to nasal topical application and at 10 hours; total bacterial counts and S. aureus bacterial counts were determined.

    Results: Of the 387 participants screened, 78(20.2%) participants tested positive for S. aureus.   A total of 39 participants were enrolled in the treatment phase of the study with 20 treated with NOZIN® and 19 receiving placebo.  Three-times daily use of the NOZIN® Nasal Sanitizer® antiseptic significantly (F(1,76)=5.478, p=0.025) reduced the number of nasal bacterial colonies from 1386.30±1861.20 at baseline to 161.80±301.09 at the end of the 10-hour study period.  Furthermore, NOZIN® Nasal Sanitizer® reduced (F(1,77)=3.059, p=0.089) the number of S. aureus colonies 660.45±1490.32 at baseline to 34.30±54.04.  Nineteen (95%) of out twenty subjects showed significant reduction (p<0.05) in S. aureus, and all 20 (100%) subjects showed significant (p<0.05) reduction in nasal bacteria.  There were no adverse events with the use of NOZIN® Nasal Sanitizer® antiseptic.

    Conclusion: NOZIN® Nasal Sanitizer® was found to be very effective in reducing S. aureus and nasal bacterial carriage.  A broader clinical trial should be conducted to determine if reducing HCP S aureus nasal carriage will reduce patient infections.

    Lisa Steed, PhD1, Justin Costello, BA2, Shivangi Lohia, MD2, Taylor Jones, BS2, Ernst Wm Spannhake, PhD3 and Shaun Nguyen, MD, MA, CPI2, (1)Pathology and Laboratory Medicine, Medical University of South Carolina, Charleston, SC, (2)Department of Otolaryngology, Head & Neck Surgery, Medical University of South Carolina, Charleston, SC, (3)Department of Environmental Health Sciences, Johns Hopkins School of Public Health, Baltimore, MD

    Disclosures:

    L. Steed, None

    J. Costello, None

    S. Lohia, None

    T. Jones, None

    E. W. Spannhake, Global Life Technologies Corp.: Grant Investigator, Research grant

    S. Nguyen, None

    Findings in the abstracts are embargoed until 12:01 a.m. PST, Oct. 2nd with the exception of research findings presented at the IDWeek press conferences.